Drug Profile
Insulin efsitora alfa - Eli Lilly and Company
Alternative Names: Basal Insulin-FC - Eli Lilly and Company; LY-3209590Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- Class Antihyperglycaemics; Immunoglobulin Fc fragments; Insulins; Pancreatic hormones; Recombinant fusion proteins
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 15 Apr 2024 Eli Lilly and Company plans a phase I trial for Type 2 diabetes mellitus (In adolescents, In children) in the USA (SC) (NCT06362265)
- 07 Dec 2023 Phase-I clinical trials in Type 2 diabetes mellitus in Germany (SC) (NCT06169982)
- 06 Dec 2023 Eli Lilly and Company plans a phase I trial for Type 2 diabetes mellitus (Treatment-naïve) in Germany (SC) (NCT06169982) (EudraCT2023-508008-39-00) in December 2023